E. Koenig

Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054

Laura Fanning, Serena Hung, Aaron Ellenbogen et al. · Movement Disorders · 2019 · 194 citations · Full text

Life Sciences, Neurology, Pharmacology +17

Safety, tolerability, and pharmacokinetics of casimersen in patients with <scp>D</scp>uchenne muscular dystrophy amenable to exon <scp>45</scp> skipping: A randomized, double‐blind, placebo‐controlled, dose‐titration trial

Kathryn R. Wagner, Nancy L. Kuntz, E. Koenig et al. · Muscle & Nerve · 2021 · 151 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +14

Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial

Laurent Servais, Eugenio Mercuri, Volker Straub et al. · Nucleic Acid Therapeutics · 2021 · 126 citations · Full text

Medicine, Pharmacotherapy, Rehabilitation Medicine +14

Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial

Craig M. McDonald, Perry B. Shieh, Hoda Abdel‐Hamid et al. · Journal of Neuromuscular Diseases · 2021 · 115 citations · Full text

Pharmacy, Pharmacotherapy, Medical Genetics +15

The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy

Dominic Scaglioni, Francesco Catapano, Matthew J. Ellis et al. · Acta Neuropathologica Communications · 2021 · 37 citations · Full text

Medicine, Molecular Medicine, Pathology +11